Material and Methods: Thirty-eight naive phakic patients who underwent unilateral intravitreal ranibizumab injection comprised the study group. Fellow uninjected eyes were regarded as control group. Central corneal thickness (CCT), anterior chamber depth (ACD), iridocorneal angle (ICA) 0°-180°, angle opening distance at Swalbe?s line (SL-AOD) 0°-180° with Visante OCT were measured before and fi rst day, first week and first month after the intravitreal ranibizumab injection.

Results: Twenty patients (%53) were male and 18 (%47) were female. Mean age was 69±11.2 years (Range;41-90 year). Ranibizumab was injected in 24 patients (%63) for wet type age-related macular degeneration; in eight patients (%21) for diabetic macular edema and in six patients (%16) for retinal vein occlusion. There was not any statistically signifi cant difference at CCT, ACD, ICA 0°-180°, SL-AOD 0°-180° between study and control eyes (p values; 0.768, 0.886, 0.800, 0.578, 0.725, 0.705, respectively). There was not any statistically significant changes at ICA 0°-180° and SL-AOD 0°-180° before and first day, first week and first month after the intravitreal ranibizumab injection in study eyes (p values, ?0.05).

Conclusion: Intravitreal ranibizumab injection does not cause any clinically signifi cant changes on the anterior chamber parameters and irido-corneal angle in treatment-naive phakic eyes. Keywords : Anterior segment optical coherence tomography, intravitreal injection, ranibizumab